Open AccessNew coronavirus infection (COVID-19): from the dermatologist’s view
Author(s) -
Olga Yu. Olisova,
Ekaterina M. Anpilogova
Publication year - 2020
Publication title -
vestnik rossijskoj akademii medicinskih nauk
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.122
H-Index - 15
eISSN - 2414-3545
pISSN - 0869-6047
DOI - 10.15690/vramn1359
Subject(s) - medicine , dermatology , ustekinumab , secukinumab , ixekizumab , covid-19 , psoriasis , asymptomatic , coronavirus , atopic dermatitis , hydroxychloroquine , adalimumab , immunology , psoriatic arthritis , pathology , disease , tumor necrosis factor alpha , infectious disease (medical specialty)
Recently published data on the pathogenesis and cutaneous manifestations of a new coronavirus infection (COVID-19) are presented. The most described lesions are urticarial, papulo-vesicular, erythematous rash, purpura, livedo-angiitis, as well as chilblains. Eruptions mainly appear together with main COVID-19 symptoms or a few days later. The treatment of new coronavirus infection may lead to a quick regression of skin lesions along with improvement of the general state of the patient. The review also provides data on the fact that COVID-19 patients with severe psoriasis and atopic dermatitis receiving biologic therapy (guselkumab, ustekinumab, adalimumab, secukinumab, ixekizumab, etanercept, dupilumab) and phosphodiesterase-4 inhibitors experience mild or asymptomatic COVID-19. Moreover, such patients do not develop cutaneous manifestations of COVID-19. The specific COVID-19 treatment has not been developed yet. We think that these findings might provide better understanding of mechanisms of action of biologic drugs in COVID-19.